Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: 3 | Mind Blowing Facts

Looking Into Viatris's Return On Capital Employed

According to Benzinga Pro, during Q1, Viatris (NASDAQ:VTRS) earned $399.20 million, a 251.33% increase from the preceding quarter. Viatris's sales decreased to $4.19 billion, a 3.45% change since Q4.

Benzinga · Jun 3, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022

Upgrades

Benzinga · May 10, 2022

Expert Ratings for Viatris

Analysts have provided the following ratings for Viatris (NASDAQ:VTRS) within the last quarter:

Benzinga · May 10, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus

Viatris Inc (NASDAQ:VTRS) reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the consensus of $4.23 billion. Brands performed better than expectations, such as Lipitor, Effexor, and Perforomist. Complex generics and biosimilars grew by 21% Y/Y on an operational basis, driven mainly by the generic…

Benzinga · May 9, 2022

Viatris Q1 2022 Earnings Conference Call On May 9, 2022 At 08:30 AM ET

Viatris (NASDAQ:VTRS) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.

Benzinga · May 4, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Upgrades

Benzinga · Mar 1, 2022

Viatris's Return On Capital Employed Overview

Benzinga Pro data, Viatris (NASDAQ:VTRS) reported Q4 sales of $4.34 billion. Earnings fell to a loss of $263.80 million, resulting in a 184.69% decrease from last quarter. Viatris earned $311.50 million, and sales totaled $4.54 billion in Q3.

Benzinga · Mar 1, 2022

Read news from The Economist, FT, and more,
with one subscription

Why Viatris Shares Are Trading Lower Today

Viatris Inc (NASDAQ: VTRS) is trading lower Monday after the company reported worse-than-expected top-line results for the fourth quarter and issued guidance below estimates.

Benzinga · Feb 28, 2022

Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters

Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has

Benzinga · Feb 28, 2022

India-Based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal

Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ:VTRS) biosimilars assets for up to $3.335 billion in stock and cash. The deal value includes cash of up to $2.335 billion and Compulsorily Convertible Preference Shares in Biocon Biologics, valued at $1 billion. Viatris will also pay $50 million to Biocon Biologics to fund…

Benzinga · Feb 28, 2022

A Bullish Sign Appears On Viatris's Chart

If history is any guide, there may be good fortune ahead for shares of Viatris (NASDAQ:VTRS). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga · Feb 16, 2022

Viatris Recalls One Batch Of Diabetes Treatment Semglee Citing Missing Label Risks

Viatris Inc's (NASDAQ: VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection.

Benzinga · Jan 20, 2022

1 2 3

Coverage From

People

Shaw

125 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Palantir Technologies

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.